Related Experiment Video
Updated: Feb 5, 2026

Orthotopic Implantation of Patient-Derived Cancer Cells in Mice Recapitulates Advanced Colorectal Cancer
Published on: February 10, 2023
Personalized Management of Advanced Kidney Cancer
Jeffrey Graham1, Daniel Y C Heng1, James Brugarolas1
1From the Tom Baker Cancer Centre, University of Calgary, Calgary, Alberta, Canada; Kidney Cancer Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX; Karmanos Cancer Institute, Wayne State University, Detroit, MI.
Abstract:
The treatment of renal cell carcinoma represents one of the great success stories in translational cancer research, with the development of novel therapies targeting key oncogenic pathways. These include drugs that target the VEGF and mTOR pathways, as well as novel immuno-oncology agents. Despite the therapeutic advancements, there is a paucity of well-validated prognostic and predictive biomarkers in advanced kidney cancer. With a number of highly effective therapies available across multiple lines, it will become increasingly important to develop a more tailored approach to treatment selection. Prognostic clinical models, such the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model, are routinely used for prognostication in clinical practice. The IMDC model has demonstrated a predictive capability in the context of these treatments including immune checkpoint inhibition. A number of promising molecular markers and gene expression signatures are being explored as prognostic and predictive biomarkers, but none are ready to be widely used for treatment selection. In this review, we will explore the current landscape of personalized care in metastatic renal cell carcinoma. This will include a focus on both prognostic and predictive factors as well as clinical applications of biology in kidney cancer.
Insights
Personalized medicine is advancing for advanced kidney cancer, but validated biomarkers are needed. This review explores prognostic and predictive factors for tailored treatment selection in renal cell carcinoma.
Area of Science:
- Oncology
- Translational Cancer Research
- Biomarker Discovery
Background:
- Renal cell carcinoma (kidney cancer) treatment has seen success through targeted therapies (VEGF, mTOR) and immuno-oncology.
- Despite advances, validated prognostic and predictive biomarkers for advanced kidney cancer are lacking.
- Tailored treatment selection is crucial due to multiple effective therapies available.
Purpose of the Study:
- To review the current landscape of personalized care in metastatic renal cell carcinoma.
- To focus on prognostic and predictive factors for kidney cancer treatment.
- To explore the clinical applications of molecular biology in kidney cancer.
Main Methods:
- Review of current literature on targeted therapies and immuno-oncology for renal cell carcinoma.
- Analysis of prognostic clinical models like the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model.
- Exploration of emerging molecular markers and gene expression signatures.
Main Results:
- Targeted therapies (VEGF, mTOR) and immuno-oncology agents have improved outcomes in kidney cancer.
- The IMDC model is a validated prognostic tool, showing predictive capability for treatments including immune checkpoint inhibitors.
- Promising molecular markers and gene signatures are under investigation but not yet clinically validated for treatment selection.
Conclusions:
- Personalized care strategies are essential for optimizing treatment selection in advanced renal cell carcinoma.
- Further research is needed to validate novel biomarkers for routine clinical use.
- Integrating biological insights into clinical practice will enhance tailored treatment approaches for kidney cancer patients.
Related Concept Videos
Cardiopulmonary Resuscitation V: Advanced Airway Management Techniques
Kidney Transplant III: Nursing Management
Acute Kidney Injury VI: Nursing Management
Chronic Kidney Disease IV: Nursing Management
Kidney Structure
Personal Identity

